secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0000939767-24-000054
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q1: revenue $425M, GAAP EPS $0.12, non-GAAP $0.17, restructuring $32.8M
--------------------------------------------------------------------------------

- Total revenues $425.2M, up 4% YoY from $408.8M; cabozantinib U.S. net product revenues $378.5M, up from $363.4M.
- GAAP net income $37.3M ($0.12 diluted EPS); non-GAAP net income $52.0M ($0.17 diluted EPS) vs $52.8M ($0.16) in Q1 2023.
- Recorded $32.8M restructuring expenses (severance, asset impairment, contract termination) from January 2024 restructuring.
- Pipeline: three ongoing pivotal trials for zanzalintinib; phase 1 studies for XB002 (ADC) and XL309 (USP1 inhibitor); up to three IND filings expected in 2024.
- Ongoing cabozantinib IP litigation with MSN Pharmaceuticals; second bench trial ruling expected spring 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000054/0000939767-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000054/exel-20240430.htm
  HTML page:      https://secwatch.observer/filing/0000939767-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer